NeuroEM reports positive data from Alzheimer’s TEMT and MemorEM trial

7 August 2019 (Last Updated August 7th, 2019 11:36)

NeuroEM Therapeutics has reported positive data from the trial of a transcranial electromagnetic treatment (TEMT) with the company’s investigational MemorEM head device to treat Alzheimer’s disease (AD).

NeuroEM reports positive data from Alzheimer’s TEMT and MemorEM trial
The study assessed the safety and initial efficacy of TEMT with the company’s investigational MemorEM head device. Credit: NeuroEM Therapeutics, Inc.

NeuroEM Therapeutics has reported positive data from the trial of a transcranial electromagnetic treatment (TEMT) with the company’s investigational MemorEM head device to treat Alzheimer’s disease (AD).

The two-month in-home trial results demonstrate that TEMT, which uses both magnetic and electric waves, was safe in all eight participating patients with mild to moderate AD.

It also enhanced cognitive performance in seven of them, as measured by standard cognition scales.

No patients complained of headaches, brain sensations or any other TEMT side effects during or following treatment and no treatment-related adverse events (AEs) were found.

Post-treatment, brain scans also revealed no visible induction of tumours or brain bleedings.

NeuroEM Therapeutics CEO Dr Gary Arendash said: “Our bioengineering technology may be succeeding where drug therapy against this devastating disease has thus far failed.

“TEMT appears to be affecting the Alzheimer’s disease process through several actions directly inside neurons (brain cells), which is where we believe the disease process needs to be stopped and hopefully reversed.”

The trial is said to be the first to administer electromagnetic waves to the entire human brain over an extended period of two months.

TEMT also showed effects on Alzheimer’s markers in blood and the cerebrospinal fluid around the brain.

The single centre, single arm pilot trial in eight patients aged 63 and above with mild to moderate AD evaluated the safety and initial efficacy of TEMT.

The subjects were enrolled at the University of South Florida Health/Byrd Alzheimer’s Institute, which also conducted all clinical study assessments.